Currently Viewing:
Supplements Improving Provider and Patient Acceptance of Biosimilars in Treating Cancer: Clinical, Manufacturing, and Cost Considerations
The Complexities of Biosimilars and the Regulatory Approval Process
Steven Lucio, PharmD, BCPS
Currently Reading
Opportunities and Challenges in Biosimilar Uptake in Oncology
Carina Dolan, PharmD, BCOP
Posttest

Opportunities and Challenges in Biosimilar Uptake in Oncology

Carina Dolan, PharmD, BCOP
There are now 10 approved biosimilars in the United States, including      3 oncology drugs, and at least 16 others in late-stage development. The introduction of competition into the biologic space launches a new era in the treatment of cancer, possibly increasing access to the extremely costly biologics. The most important and influential stakeholders for biosimilar acceptance and usage are healthcare providers, such as pharmacists and physicians, as well as patients. Gaining their support requires extensive education, postmarketing pharmacovigilance, resolving concerns about immunogenicity, and allowing interchangeability and substitution. Patients require education on the basic definition of biosimilars versus generic drugs, how biosimilars are tested and approved, costs, and availability of clinical trials. Meanwhile, payers may need to find ways to incentivize physicians to prescribe biosimilars over biologics, as well as to provide information on cost and quality directly to patients in order to drive uptake. Finally, legal challenges to approved and pending biosimilars have limited the market access of these agents.
Am J Manag Care. 2018;24(11):-S0

Become a Member to see the rest of this article and get access to all of our articles and resources. Membership is Free!

Register
Login
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up